|1.||Doerge, Daniel R: 5 articles (11/2012 - 06/2004)|
|2.||Churchwell, Mona I: 3 articles (05/2009 - 06/2004)|
|3.||Alexander, Jan: 2 articles (12/2012 - 11/2007)|
|4.||Törnqvist, Margareta: 2 articles (12/2012 - 08/2008)|
|5.||Beland, Frederick A: 2 articles (11/2012 - 05/2009)|
|6.||Von Tungeln, Linda S: 2 articles (11/2012 - 05/2009)|
|7.||Olesen, Pelle Thonning: 2 articles (06/2012 - 05/2008)|
|8.||Overvad, Kim: 2 articles (06/2012 - 05/2008)|
|9.||Frandsen, Henrik: 2 articles (06/2012 - 05/2008)|
|10.||Olsen, Anja: 2 articles (06/2012 - 05/2008)|
04/01/2009 - "Quantitative inclusion of these TK/TD factors will more closely estimate actual human cancer risk derived from high-dose rodent studies, since detoxification processes for acrylamide and glycidamide appear adequately protective against toxicity from human dietary doses."
02/27/2013 - "Dose dependent molecular effects of acrylamide and glycidamide in human cancer cell lines and human primary hepatocytes."
01/01/2011 - "For assessment of cancer risk from acrylamide (AA) exposure through food, the relation between intake from food in humans and the in vivo doses (area under the concentration-time curve, AUC) of AA (AUC-AA) and of its genotoxic metabolite glycidamide (GA) (AUC-GA) is used as a basis for extrapolation between exposure levels and between species. "
10/01/2008 - "Regarding the cancer risk assessment of acrylamide (AA) it is of basic interest to know, as to what amount of the absorbed AA is metabolized to glycidamide (GA) in humans, compared to what has been observed in laboratory animals. "
08/13/2008 - "One point of discussion is whether AA constitutes a cancer risk through its genotoxic metabolite, glycidamide (GA), or whether other mechanism(s) could be operating. "
|2.||Birth Weight (Birth Weights)
|3.||Body Weight (Weight, Body)
06/30/2004 - "A toxicokinetic study of AA and its epoxide metabolite, glycidamide, was performed by switching mice from NIH-31IR to the autoclaved diet for a 30 min feeding period (average AA dose administered was 4.5 microg/kg of body weight). "
11/01/2012 - "Male B6C3F(1) mice were injected intraperitoneally on postnatal days 1, 8 and 15 with 0.0, 0.14 or 0.70 mmol acrylamide or glycidamide per kg body weight per day and the tumorigenicity was assessed after 1 year. "
05/01/2009 - "Male and female B6C3F1/Tk mice were treated intraperitoneally on postnatal days (PNDs) 1, 8 and 15 or PNDs 1-8 with 0.14 or 0.70 mmol acrylamide or glycidamide per kg body weight per day. "
11/01/2007 - "injected with 10 or 50 mg/kg body weight (bw) of AA or glycidamide (GA) at week 1 and 2 after birth. "
06/01/2010 - "In the present study, we exposed Big Blue rats to the equivalent of approximately 5 and 10 mg/kg body weight/day of AA or its epoxide metabolite glycidamide (GA) via the drinking water, an AA treatment regimen comparable to those used to produce cancer in rats. "
|4.||Breast Neoplasms (Breast Cancer)
06/14/2012 - "The aim of the present study was to evaluate if pre-diagnostic acrylamide exposure, measured by acrylamide and glycidamide hemoglobin adducts (AA-Hb and GA-Hb), were associated to mortality in breast cancer cases. "
05/01/2008 - "A weak association between glycidamide hemoglobin levels and incidence of estrogen receptor positive breast cancer was also found, this association, however, entirely disappeared when acrylamide and glycidamide hemoglobin levels were mutually adjusted."
05/01/2008 - "N-terminal hemoglobin adduct levels of acrylamide and its genotoxic metabolite, glycidamide in red blood cells were analyzed (by LC/MS/MS) as biomarkers of exposure on 374 breast cancer cases and 374 controls from a cohort of postmenopausal women. "
|2.||Biological Markers (Surrogate Marker)
|3.||Proteins (Proteins, Gene)
|4.||Protamines (Protamine Sulfate)
|7.||DNA (Deoxyribonucleic Acid)